We have observed
56 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after July 02, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
METHOD FOR TREATING LIVER INFLAMMATION, FIBROSIS AND NON-ALCOHOLIC STEATOHEPATITIS.
METHOD FOR ENCAPSULATED THERAPEUTIC PRODUCTS AND USES THEREOF
IN VITRO METHOD FOR PREDICTING IN VIVO GENOTOXICITY OF CHEMICAL COMPOUNDS
In vitro method for predicting disease outcome in stage II colorectal cancer
METHOD FOR THE PREVENTION AND TREATMENT OF SEPSIS
A NEW CLASSIFIER FOR THE MOLECULAR CLASSIFICATION OF MULTIPLE MYELOMA
Therapeutic cancer vaccines derived from a novel dendritic cell line
NEW METHOD AND KIT FOR PREDICTION SUCCESS OF IN VITRO FERTILIZATION
ENZYME VARIANTS WITH IMPROVED PROPERTIES
In vitro method for determining skin sensitizing potential.
In vitro method for determining cholestatic properties of a compound.
Method for preventing or reducing postoperative adhesions
In vitro method for predicting whether a compound is genotoxic in vivo.
Method for the preparation of a dry composition comprising a stable ABTS radical
Method for the treatment of lysozomal lipid storage diseases
Aminomethylene pyrazolones with therapeutic activity
Method for determining hepatotoxicity of a compound.
In vitro method for determining immunotoxicity of a compound
Method for determining the risk of developing severe dyspnea after radiation therapy
Method for the in vitro maturation of dendritic cells
A human dendritic cell line
Composition having a beneficial effect on the cardiovascular system, comprising monacolin K, lycopene and vitamin D3
AMINOMETHYLENE PYRAZOLONES WITH THERAPEUTIC ACTIVITY
Method for predicting the skin sensitizing activity of a compound.
In vitro method for determining pertussis toxin activity
IN VITRO METHOD FOR PREDICTING DISEASE OUTCOME IN STAGE II COLORECTAL CANCER
In vitro method for determining genotoxic and non-genotoxic carcinogenicity of a compound.
Contrast agent and its use for imaging.
METHOD FOR THE IN VITRO MATURATION OF DENDRITIC CELLS
METHOD FOR LOADING OF DENDRITIC CELLS WITH CLASS I ANTIGENS
CONTRAST AGENT AND ITS USE FOR IMAGING
THERAPEUTIC CANCER VACCINES DERIVED FROM A NOVEL DENDRITIC CELL LINE
METHOD FOR SAVING ENERGY IN PAPER PRODUCTION
METHOD FOR IMPROVING THE FERMENTABLE SUGAR YIELD FROM LIGNOCELLULOSIC SUBSTRATES
BLASTOID, CELL LINE BASED ARTIFICIAL BLASTOCYST
A system for stabilization of at least a portion of a spinal column as well as an anchor member suitable for such a system
METHOD FOR DETERMINING THE RISK OF DEVELOPING RADIATION-INDUCED TOXICITY AFTER EXPOSURE TO RADIATION
COMPOSITION HAVING A BENEFICIAL EFFECT ON THE CARDIOVASCULAR SYSTEM, COMPRISING MONACOLIN K, LYCOPENE AND VITAMIN D3
In vitro method for determining disease outcome in pulmonary carcinoids.
TREATMENT OF COGNITIVE IMPAIRMENT WITH COMBINATION THERAPY
TREATMENT OF COGNITIVE IMPAIRMENT WITH PDE4 INHIBITOR
METHOD FOR THE TREATMENT OF DIABETES MELLITUS
Method for determining the neurodevelopmental toxicity of a compound in vitro.
METHOD FOR REDUCING THE INFLAMMATORY ACTIVITY OF A STEM CELL TRANSPLANT AND USE THEREOF
METHOD FOR SUPPRESSING AN IMMUNE RESPONSE
METHOD FOR RESTORING IMMUNE TOLERANCE IN VIVO
ANTI-INFLAMMATORY AGENTS DIRECTED AGAINST CITRULLINATED EPITOPES
NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES AGAINST HEPATITIS B VIRUS SURFACE ANTIGEN
METHOD FOR DETERMINING THE LEVEL OF HYPOXIA IN A TUMOR
LACCASE VARIANTS WITH IMPROVED PROPERTIES
MICRORNAS FOR THE TREATMENT OF HEART DISEASES
METHOD FOR THE SEROLOGICAL DIAGNOSIS OF RHEUMATOID ARTHRITIS.
IN VITRO METHOD FOR DETERMINING IMMUNOTOXICITY OF A COMPOUND
METHOD FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS